Why a ranitidine shortage is likely
Ranitidine products are likely to be recalled due to contamination concerns, says the TGA.
The regulator is testing local samples following international reports of contamination with an impurity called N‑nitrosodimethylamine (NDMA).
A recall is “anticipated”, the watchdog said.
The TGA has advised pharmacists to discuss alternative treatments with patients and to consider if ongoing therapy is warranted.
But it has also warned pharmacists there may be shortages of alternative medicines as a result of the ranitidine issue.